In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

DNA Ginkgo Bioworks Holdings, Inc.

Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Members of the far-right group Patriot Front march through Washington, DC, on May 13, 2023. Nathan Posner/Anadolu Agency via Getty Images For CFR’s annual Preventive Priorities Survey, U.S. foreign ...

SINCE its first announcement by Dr. E. P. Hubble in 1929, the existence of a linear relation between Velocity’ and distance among the extra-galactic nebulae has excited a great deal of theoretical ...

Abstract: Multi-Depot Vehicle Routing Problem (MDVRP) requires constructing routes from multiple depots to geographically dispersed customers under capacity constraints. Unlike single-depot routing ...

The future of defense strategy requires restructuring forces for modern threats, focusing deployments on critical regions, accelerating tech integration, reforming procurement and budgets, ...